DIABETES OBESITY & METABOLISM (ELECTRONIC),volume 1462-8902,issue 10  (10-2015)

Period of time： 2015年10期

Publisher： John Wiley & Sons Inc

Founded in： 1999

Total resources： 46

E-ISSN： 1463-1326|1462-8902|10

ISSN： 1462-8902

Subject： R Medicine and Health

Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

DIABETES OBESITY & METABOLISM (ELECTRONIC),volume 1462-8902,issue 10

Menu

Diabetes, Obesity and Metabolism

DIABETES OBESITY & METABOLISM (ELECTRONIC),volume 1462-8902,issue 10 , Vol. 1462-8902, Iss. 10, 2015-10 , pp. i-i

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Biosimilar insulins: guidance for data interpretation by clinicians and users

DIABETES OBESITY & METABOLISM (ELECTRONIC),volume 1462-8902,issue 10 , Vol. 1462-8902, Iss. 10, 2015-10 , pp. 911-918

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Weight‐sparing effect of insulin detemir: a consequence of central nervous system‐mediated reduced energy intake?

DIABETES OBESITY & METABOLISM (ELECTRONIC),volume 1462-8902,issue 10 , Vol. 1462-8902, Iss. 10, 2015-10 , pp. 919-927

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1)

DIABETES OBESITY & METABOLISM (ELECTRONIC),volume 1462-8902,issue 10 , Vol. 1462-8902, Iss. 10, 2015-10 , pp. 928-935

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

DIABETES OBESITY & METABOLISM (ELECTRONIC),volume 1462-8902,issue 10 , Vol. 1462-8902, Iss. 10, 2015-10 , pp. 936-948

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial

DIABETES OBESITY & METABOLISM (ELECTRONIC),volume 1462-8902,issue 10 , Vol. 1462-8902, Iss. 10, 2015-10 , pp. 949-955

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy

DIABETES OBESITY & METABOLISM (ELECTRONIC),volume 1462-8902,issue 10 , Vol. 1462-8902, Iss. 10, 2015-10 , pp. 956-964

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial

DIABETES OBESITY & METABOLISM (ELECTRONIC),volume 1462-8902,issue 10 , Vol. 1462-8902, Iss. 10, 2015-10 , pp. 965-973

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study

DIABETES OBESITY & METABOLISM (ELECTRONIC),volume 1462-8902,issue 10 , Vol. 1462-8902, Iss. 10, 2015-10 , pp. 974-983

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus

DIABETES OBESITY & METABOLISM (ELECTRONIC),volume 1462-8902,issue 10 , Vol. 1462-8902, Iss. 10, 2015-10 , pp. 984-993

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Previous 1 2 Next Display item(s) per page Total 13 item(s)